Glucagon-Like Peptide 1 Weight Loss: Market Trends, Brand Efficacy, and Peptide Technology Analysis
Abstract: The glucagon-like peptide-1 (GLP-1) weight loss market is projected to exceed $100 billion by 2030, driven by semaglutide (Novo Nordisk’s Wegovy/Ozempic) and tirzepatide (Eli Lilly’s Zepbound/Mounjaro). Clinical data show 15–22% body weight reduction over 68 weeks. Peptide technology advances (e.g., fatty acid acylation, DPP-4 resistance) enhance half-life (7 days vs. 2 minutes for native GLP-1). Brand efficacy comparison reveals semaglutide superior in cardiovascular outcomes, while tirzepatide (dual GIP/GLP-1 agonist) achieves greater weight loss. Product parameters: dosing (0.25–2.4 mg weekly), purity (>99% HPLC), and cold-chain logistics (2–8°C) are critical. Regulatory certifications (FDA, EMA, GMP) ensure safety. Selection criteria prioritize clinical trial data, manufacturer transparency, and stability testing. Industry trends include oral formulations and combination therapies.